AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Single-Dose YKYY029, an Angiotensinogen-Targeting Small Interfering RNA, in Healthy and Mildly Hypertensive Subjects: A Phase 1 Study

By Wang F, Huang Z, Zhou Y et al.

Background: Angiotensinogen (AGT), produced predominantly by the liver, is the exclusive precursor for angiotensin peptides and the most upstream substrate of the renin-angiotensin-aldosterone system (RAAS). Sustained hepatic AGT silencing may provide long-acting blood pressure (BP) lowering and help overcome the severe adherence limitations of daily oral pharmacotherapy. YKYY029 is a novel GalNAc-conjugated small interfering RNA (siRNA) designed to potently and selectively silence hepatic AGT mRNA expression. Research Question/Hypothesis: We evaluated whether a single subcutaneous dose of YKYY029 would produce early and sustained AGT lowering, accompanied by exploratory ambulatory BP reductions, while maintaining an acceptable safety profile. Methods: This ongoing randomized, double-blind, placebo-controlled, single-ascending-dose phase 1 study enrolled Chinese healthy volunteers and adults with mild essential hypertension who were untreated or off antihypertensive therapy for >=4 weeks. Participants received a single abdominal subcutaneous injection of YKYY029 (50, 150, 300, 600, or 800 mg) or placebo (6:2 allocation per cohort). Safety, serum AGT, anti-drug antibodies, ambulatory BP, and office BP were assessed through 12 weeks. Results: Forty participants were dosed (YKYY029, n=30; placebo, n=10; baseline 24-hour ambulatory BP, 127.9/82.3 mm Hg). No deaths, serious adverse events, adverse events of special interest, TEAE-related interruption/discontinuation, related grade >=3 TEAEs, hypotension/syncope, or anti-drug antibodies occurred. Injection-site erythema and pain each occurred in 1/30 YKYY029-treated participants. Serum AGT reductions were rapid, dose-associated, and durable: by Day 30, mean reductions were 88.2%, 94.8%, 92.5%, 97.9%, and 97.4% for the 50, 150, 300, 600, and 800 mg groups, respectively, and remained 81.8%, 93.2%, 94.0%, 97.6%, and 97.9% at Day 85 (study ongoing; Figure 1). At Day 85, 24-hour ambulatory SBP changes across 50/150/300/600/800 mg were -9.7/-12.5/-4.8/-11.0/-17.7 mm Hg (placebo +1.4). For 150/800 mg, 24-hour SBP/DBP changes were -12.5/-12.5 and -17.7/-11.8 mm Hg; descriptive placebo-adjusted changes were -13.9/-8.0 and -19.1/-7.3 mm Hg; SBP percent changes were -9.7% and -13.5% versus +1.2% with placebo. Daytime/nighttime SBP/DBP changes were -13.3/-13.5 and -11.5/-8.5 mm Hg at 150 mg, and -18.8/-12.8 and -13.7/-9.3 mm Hg at 800 mg (Figure 2). Conclusions: A single dose of YKYY029 was generally well tolerated and produced highly rapid, near-complete, sustained hepatic AGT suppression with both daytime and nighttime ambulatory BP reductions through Week 12. These findings support the continued clinical advancement of YKYY029 as an infrequent, long-acting foundational therapy for hypertension management.

doi.org/10.1161/circ.154.suppl_1.6689Interventions

AgingResearch.News